^
Association details:
| Biomarker: | PTEN mutation + TP53 mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The role of PTEN and TP53 co-mutations in immunotherapy of lung cancer.
Published date:
05/19/2021
Excerpt:
The median progression-free survival (PFS) in the PTEN and TP53 co-mutations group was the longest (7.5 months), while the median PFS in the PTEN mutations without TP53 mutations group was only 2.5 months....patients with NSCLC harboring PTEN and TP53 co-mutations might benefit more from immunotherapy compare to those harboring PTEN mutation without TP53 mutations and PTEN wild-type.
DOI:
10.1200/JCO.2021.39.15_suppl.e21161
